Capstone Investment Advisors
ASND icon

Capstone Investment Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Capstone Investment Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,681
Closed -$464K – 2331
2023
Q4 		$464K Buy
3,681
+9
+0.2% +$897 ﹤0.01% 1377
2023
Q3 		$344K Buy
+3,672
New +$344K ﹤0.01% 1526

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capstone Investment Advisors's ASND Position: Q1 2024 in Review

Capstone Investment Advisors sold out of Ascendis Pharma A/S (ASND) in Q1 2024, closing a stake of 3,681 shares — an estimated $464K sold.

Capstone Investment Advisors first reported a position in ASND in Q3 2023 and held it in 2 quarters. The position peaked at $464K in Q4 2023. 189 funds tracked by Wall St. Rank hold ASND as of Q1 2024.

  • Capstone Investment Advisors reported no remaining Ascendis Pharma A/S position as of Q1 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 3,681 Ascendis Pharma A/S shares in Q1 2024, an estimated $464K.
  • Capstone Investment Advisors first reported a position in Ascendis Pharma A/S in Q3 2023 and held it in 2 quarters.
  • Capstone Investment Advisors's Ascendis Pharma A/S position peaked at $464K in Q4 2023.
  • 189 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2024.

Based on Capstone Investment Advisors's 13F filing for Q1 2024, filed 1 May 2024.